Navigation Links
Kite Pharma Appoints Cynthia M. Butitta as Chief Financial Officer
Date:1/8/2014

LOS ANGELES, Jan. 8, 2014 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT™) products for cancer, today announced the appointment of Cynthia M. Butitta to the newly created position of Executive Vice President and Chief Financial Officer.  A veteran financial and operational executive, Ms. Butitta brings over 20 years' experience in leadership roles in the biotech and technology industries.  Her appointment is effective immediately.

(Logo: http://photos.prnewswire.com/prnh/20130513/MM13332LOGO)

Arie Belldegrun, M.D., Founder and Executive Chairman of the Board of Kite Pharma, commented, "Cindy has an outstanding track record and depth and breadth of experience in capital fund raising, strategic planning and investor relations at both private and public biotechnology companies.  We are delighted to welcome her to the team and believe her unique capabilities and expertise will greatly benefit Kite as we pursue our clinical and business objectives."

Prior to joining Kite, Ms. Butitta served as Senior Vice President, Chief Financial Officer of NextWave Pharmaceuticals.  During her tenure, Ms. Butitta was responsible for finance and administration, distribution and project management and played a key role in the Company's acquisition by Pfizer, Inc. for $700 million.  Previously, she was Chief Financial Officer and Chief Operating Officer of Telik, Inc.  At Telik, Ms. Butitta was responsible for securing over $450 million through an IPO and subsequent follow-on offerings and oversaw financial reporting and controls, investor relations, information technology, manufacturing, quality, project management and commercial operations.  Previously, she served as Vice President of Finance and Administration and Chief Financial Officer for Connetics, Inc., a public biotechnology company.  Ms. Butitta received her B.S. degree with honors in Business and Accounting from Edgewood College in Madison, Wisconsin and her MBA degree in Finance from the University of Wisconsin, Madison.

Ms. Butitta stated, "I am thrilled to join the accomplished executive management team at Kite.  As a leading company in the emerging and highly promising field of immunotherapy, Kite has the opportunity to play a pivotal role in changing the way we approach cancer.  It is an exciting time for the Company, with recent clinical breakthroughs reported at a major cancer conference, and I look forward to contributing to Kite's continued evolution and growing presence within the life sciences industry."

About Kite Pharma

Kite Pharma, Inc. (Kite) is a privately held development stage biotechnology company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT™ designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch, Kite is advancing a pipeline of proprietary eACT™ product candidates, both CAR and TCR products, directed to a wide range of cancer indications. These novel personalized and targeted immunotherapies, which capitalize on the selectivity and potency of immune cells, are designed to provide significant and durable clinical benefit regardless of tumor origin, disease stage, and prior treatments. Kite's management team has a proven track record of building successful biotechnology companies and successfully developing cutting-edge immunotherapies and oncology treatments. Kite is based in Los Angeles, CA.  For more information, visit the company's website at http://www.kitepharma.com.

Kite Contact:
Dr. Arie Belldegrun
Executive Chairman
310-824-9999
arie@kitepharma.com

For Media:
Justin Jackson
Burns McClellan
(212) 213-0006
jjackson@burnsmc.com


'/>"/>
SOURCE Kite Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Upcoming Conferences, Share Price Updates, and Leadership Changes - Research Report on Lilly, Allergan, Waters, Novavax, and Supernus Pharmaceuticals
2. Auxilium Pharmaceuticals, Inc. To Present At The J.P. Morgan 32nd Annual Healthcare Conference
3. Questcor Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
4. Sutro Biopharma to Collaborate With Memorial Sloan-Kettering Cancer Center to Produce Bispecific Antibodies for the Treatment of Neuroblastoma
5. Kite Pharma to Present at the 32nd Annual J.P. Morgan Healthcare Conference
6. Study Updates, Notices, Quarterly Reports, and Revenue Guidance Updates - Research Report on NPS Pharmaceuticals, Oramed, PAREXEL, PhotoMedex, and Cell Therapeutics
7. Bellicum Pharmaceuticals Raises $34.4 Million in a Series B Financing
8. Velocity Pharmaceutical Development Announces Appointment of Stuart Sedlack as Senior Vice President, Business Development
9. Jazz Pharmaceuticals to Present at J.P. Morgan Healthcare Conference on January 13
10. Ralphs Pharmacies Providing Prescriptions at No Upfront Cost for Customers Enrolled in the Public Health Insurance Marketplace
11. CVS/pharmacy Helps Customers Kick Off a Healthy New Year with Online Vitamin Resources and Huge Savings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
Breaking Medicine News(10 mins):